Nordea Investment Management AB Raises Holdings in Dynavax Technologies Corporation $DVAX

Nordea Investment Management AB lifted its position in Dynavax Technologies Corporation (NASDAQ:DVAX) by 0.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 782,248 shares of the biopharmaceutical company’s stock after purchasing an additional 3,171 shares during the quarter. Nordea Investment Management AB owned about 0.65% of Dynavax Technologies worth $7,830,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale bought a new stake in Dynavax Technologies in the 1st quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd increased its position in Dynavax Technologies by 5,485.7% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,304 shares during the last quarter. GAMMA Investing LLC raised its stake in Dynavax Technologies by 88.4% during the first quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 3,627 shares in the last quarter. Callan Family Office LLC purchased a new stake in Dynavax Technologies during the second quarter valued at $107,000. Finally, Moloney Securities Asset Management LLC bought a new position in Dynavax Technologies during the first quarter valued at $131,000. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Trading Up 2.3%

Shares of DVAX opened at $10.06 on Tuesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.65 and a quick ratio of 6.01. The company has a 50-day moving average of $10.06 and a 200 day moving average of $10.38. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -21.87 and a beta of 1.13. Dynavax Technologies Corporation has a 1-year low of $9.20 and a 1-year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.02. The business had revenue of $95.44 million for the quarter, compared to the consensus estimate of $87.55 million. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%. On average, research analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DVAX. JMP Securities restated a “market outperform” rating and issued a $32.00 target price on shares of Dynavax Technologies in a report on Friday, August 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Dynavax Technologies presently has a consensus rating of “Hold” and an average target price of $24.33.

Insider Transactions at Dynavax Technologies

In other news, Director Scott Dunseth Myers bought 3,800 shares of Dynavax Technologies stock in a transaction on Friday, August 22nd. The stock was acquired at an average cost of $10.82 per share, for a total transaction of $41,116.00. Following the completion of the acquisition, the director owned 35,004 shares of the company’s stock, valued at $378,743.28. This trade represents a 12.18% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.98% of the stock is owned by company insiders.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.